10x Genomics/$TXG
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Primary listing
Employees
1,306
Headquarters
Website
10x Genomics Metrics
BasicAdvanced
$1.9B
-
-$0.62
2.19
-
Price and volume
Market cap
$1.9B
Beta
2.19
52-week high
$17.25
52-week low
$6.78
Average daily volume
2.9M
Financial strength
Current ratio
4.479
Quick ratio
3.928
Long term debt to equity
9.736
Total debt to equity
11.079
Profitability
EBITDA (TTM)
-106.888
Gross margin (TTM)
68.88%
Net profit margin (TTM)
-11.89%
Operating margin (TTM)
-21.67%
Effective tax rate (TTM)
-4.41%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-8.85%
Return on equity (TTM)
-10.12%
Valuation
Price to revenue (TTM)
2.931
Price to book
2.44
Price to tangible book (TTM)
2.67
Growth
Revenue change (TTM)
1.92%
Earnings per share change (TTM)
-59.44%
3-year revenue growth (CAGR)
8.41%
3-year earnings per share growth (CAGR)
-25.20%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Bulls say / Bears say
10x Genomics filed two patent‐infringement lawsuits against Illumina in October 2025 to protect its spatial transcriptomics and single‐cell genomics IP, potentially deterring imitators and strengthening its competitive moat (Reuters)
In Q1 2025, 10x Genomics partnered with the Arc Institute to accelerate the development of the Arc Virtual Cell Atlas by leveraging its Chromium Flex technology, potentially expanding its consumables business and reinforcing its leadership in large-scale single-cell data generation (PR Newswire)
At the 2025 AGBT General Meeting, 10x Genomics unveiled a comprehensive innovation roadmap across its Chromium, Visium, and Xenium platforms, signaling a robust product pipeline poised to drive future revenue growth (GuruFocus)
10x Genomics withdrew its full-year 2025 revenue guidance due to uncertainty in U.S. academic and government research funding—which supports 40%–50% of its revenue—reducing visibility into its financial outlook (Benzinga)
Total instrument revenue plunged 42% year-over-year to $14.8 million in Q1 2025, undermining its razor-and-blade consumables model by reducing future reagent sales (PR Newswire)
Shares of 10x Genomics fell 8.8% on NIH funding‐cut fears, highlighting the company’s sensitivity to U.S. government research budget risks that could materially impact its academic customer base (Barron's)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.9B as of November 09, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of November 09, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 2.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.